Comparative Pharmacology
Head-to-head clinical analysis: GADOBUTROL versus GADOTERATE MEGLUMINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GADOBUTROL versus GADOTERATE MEGLUMINE.
GADOBUTROL vs GADOTERATE MEGLUMINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Gadobutrol is a gadolinium-based contrast agent (GBCA) that shortens T1 relaxation time in magnetic resonance imaging (MRI), enhancing signal intensity in tissues where it distributes. It is a paramagnetic agent that increases the relaxation rate of water protons in the vicinity of the gadolinium ion.
Gadoterate meglumine is a paramagnetic contrast agent that increases the relaxation rate of water protons in tissues, thereby enhancing image contrast in magnetic resonance imaging (MRI). It is a macrocyclic gadolinium-based contrast agent (GBCA) with high thermodynamic stability and kinetic inertness, reducing the risk of gadolinium dissociation.
0.1 mmol/kg (0.1 mL/kg) intravenous bolus; maximum dose 0.1 mmol/kg per contrast study. Repeat dosing up to 0.2 mmol/kg total during a single session may be considered on clinical judgment.
0.2 mL/kg (0.1 mmol/kg) intravenously as a single bolus injection.
None Documented
None Documented
Terminal elimination half-life: 1.24-2.23 hours (healthy); may be prolonged in renal impairment (up to 9.6 hours in severe impairment).
Terminal elimination half-life approximately 1.5–2 hours in patients with normal renal function; prolonged in renal impairment (up to 12–34 hours in severe impairment).
Primarily renal (90-95% unchanged within 24 hours); less than 0.3% fecal.
Primarily renal (99% excreted unchanged in urine within 24 hours); biliary/fecal elimination negligible (<1%).
Category A/B
Category C
Contrast Agent
Contrast Agent